US Pharma News

06/28/2022

FDA Clears Barrier-Forming Nasal Spray for Allergic Rhinitis

Learn more ->

Bentrio is a drug-free, preservative-free, OTC nasal spray for protection against airborne allergens.

06/07/2022

ADA: Tirzepatide Improves Kidney Outcomes in T2DM With Increased CV Risk

Learn more ->

Fewer renal complications seen with tirzepatide versus insulin glargine in adults with T2D and increased cardiovascular risk

05/20/2022

Hospital Outcomes Worse With Suboptimal Treatment of Hypothyroidism

Learn more ->

Patients with clinical hypothyroidism and a high prehospitalization TSH level had longer length of stay, increased risk for readmission

04/22/2022

USPSTF Advises Against Hormone Therapy to Prevent Chronic Conditions

Learn more ->

USPSTF recommends against hormone therapy for primary prevention of chronic conditions in postmenopausal persons

04/14/2022

Bevacizumab Biosimilar Alymsys Gets FDA Approval

Learn more -> https://www.empr.com/home/news/bevacizumab-biosimilar-alymsys-gets-fda-approval/

04/06/2022

ACC: Treatment Beneficial for Mild Chronic HTN in Pregnancy

Learn more -> https://www.empr.com/home/news/acc-treatment-beneficial-for-mild-chronic-htn-in-pregnancy/

03/30/2022

Ozempic 2mg Dose Approved to Provide Additional Glycemic Control in Type 2 Diabetes

Learn more ->

The approval was based on data from the phase 3b SUSTAIN FORTE trial, which compared Ozempic 2mg to 1mg in adults with type 2 diabetes.

03/25/2022

FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC

Learn more -> https://www.empr.com/home/news/drugs-in-the-pipeline/fda-rejects-sintilimab-combo-for-first-line-treatment-of-nonsquamous-nsclc/

03/18/2022

Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus

Learn more ->

For percentage of patients achieving specified reduction in disease activity, iberdomide superior to placebo only at highest dose tested

03/16/2022

Gene Therapy for Hemophilia A 'Transforming and Liberating'

Learn more -> https://www.medscape.com/viewarticle/970418

03/12/2022

Allogeneic CAR T-Cell Candidate Fast Tracked for Renal Cell Carcinoma

Learn more ->

The investigational product targets CD70, which is highly expressed in renal cell carcinoma with limited normal tissue expression.